Learn

Obesity Research Review issue 10 with commentary by Professor Joseph Proietto.  

This Review features key medical articles from global journals with commentary from Professor Joseph Proietto. The Review covers topics such as bariatric surgery, BMI, cardiac and cancer risk, and maternal risk factors. 

To access this publication please click ‘Enrol Now’ and you’ll be directed to  the publication. Then sign up to Research Review at no cost. You can then login with your email and password. If you require any assistance please email Research Review – trish@researchreview.com.au

Details

We begin this issue with the double-blind SELECT RCT which showed that semaglutide reduced the risk of adverse cardiovascular events in non-diabetic adults with overweight/obesity and pre-existing cardiovascular disease.  

This is followed by an interesting paper which posits that in obesity, inflammatory and metabolic signals induce PD-1 expression on macrophages, inhibiting cancer tumour surveillance – this may explain why individuals with obesity have a higher risk of cancer, albeit with enhanced responses to PD-1 immunotherapy. The next article reports on a pre-clinical study which observed promising responses with the combination of a GLP-1 receptor agonist and an NMDA receptor antagonist (MK-801) in mouse models.  

We conclude with a large-scale analysis of more than 17 million UK individuals which reveals that during the pandemic, rapid weight gain was most likely to occur among women, younger adults, individuals living in deprived areas and those with long-term conditions, particularly depression.    

To access this publication please click ‘Enrol Now’ and you’ll be directed to  the publication. Then sign up to Research Review at no cost. You can then login with your email and password. If you require any assistance please email Research Review – trish@researchreview.com.au

This activity is accepted by CPD Home as a Domain 1: Educational Activity - Professional Reading in alignment with the CPD Home Program Guide. 

Disclaimer: Please note, once you click 'Enrol now' you will be leaving the AMA’s CPD Home website and entering a third-party website.